Abstract
The antibody-drug conjugate trastuzumab deruxtecan might become a promising new treatment option for patients with metastatic HER2-positive breast cancer whose disease has progressed after multiple therapies. In a phase II trial, the drug was associated with a high objective response rate and long median progression-free survival, although some patients developed serious side effects.
©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.